Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M865Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M1.1EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)20.6Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book5.410-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M9,000,002ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with FBT

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

FBT is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!

FBT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Honig, BarryDirector 2016-07-08Buy20,000$0.3130909.68view
Nadeau, SteveSenior Officer 2016-07-08Buy4,500$1.247652.42view
haukedal, peter lawrence10% Security Holder 2016-07-08Buy41,000$0.07137228.57view
haukedal, peter lawrence10% Security Holder 2016-07-08Buy9,000$0.07137228.57view
Roodenburg, Anthony RalphDirector, Senior Officer 2016-07-08Buy100,000$0.1563986.67view
Churcher, Dale LeeworthySenior Officer 2016-07-08Sell39,377$6.551367.63view
Sanderson, Robert KeithDirector 2016-07-08Buy15,000$0.04240225view
International Finance Corporat10% Security Holder 2016-07-08Sell1,000,000$0.05192160view
Meade, Harlan DonnleyDirector, Senior Officer 2016-07-08Buy1,500$0.1659981.25view
Meade, Harlan DonnleyDirector, Senior Officer 2016-07-08Buy4,000$0.1853305.56view

Quarterly/Annual Reports about FBT:

    News about FBT:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    What’s behind the Recent Fall in Alexion’s Valuation Multiple? Jul 25 2016
    How Much Will Orkambi Fetch for Vertex Pharmaceuticals in 2Q16? Jul 22 2016
    How Can Alexion Stay ahead of the Competition with Soliris? Jul 22 2016
    ALNY Should Complete Revusiran’s Endeavour Trial Enrollment in Late 2016 Jul 14 2016
    Biotech ETFs: Will the Once Hot Group Rebound? Jul 13 2016
    Inside Alnylam Pharmaceuticals’s Analyst Recommendations in 2016 Jul 08 2016
    Regeneron in 2Q16: How Much Revenue Growth Could It Have? Jul 08 2016
    Inside BioMarin’s Big Plans for 3Q16 Jul 06 2016
    Biotechs Building Base?...Or Bursting Bubble? Jun 30 2016
    BioMarin’s Guidance for 2016: The Inside Story Jun 29 2016
    As Cost Panel Gets Delayed, Buy These 3 Biotech ETFs Jun 23 2016
    Expect More Election Year Volatility For Biotech ETFs Jun 21 2016
    Biotech Bounce: Sizzle Or Fizzle? Jun 06 2016
    A Catalyst for Biotech ETFs Jun 06 2016
    Trying to Believe in Biotech ETFs Jun 03 2016
    Finally A Biotech ETF Bounce? Jun 01 2016
    Government Study: Cellphone Radiation Linked To Cancer May 27 2016
    10 Best Performing ETFs Year To Date May 26 2016
    Biotech ETFs Soar on Pfizer-Anacor Deal: SBIO, XBI in Lead May 17 2016
    Deals Boost Niche, Equal-Weighted ETFs May 16 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)